Moving new evidence from the lab bench to the clinical setting is critical. Our ambition is to move diagnosis to the earliest stage, to improve diagnosis and to see new prevention programmes implemented and the current ones improved. This means close working the Department of Health and Social Care, Public Health England, NHS England and all the Royal Colleges that relate to our area: Obstetricians and Gynaecologists, Pathologists and GPs. We sit on a range of public policy and professional bodies and collaborative campaigning groups, this includes Cancer 52, the Cancer Campaigning Group, and the Early Diagnosis Research Charities Coalition. In addition, clinical leads within the team provide representation on several groups including the National Forum for Gynae Oncology Nurses, British Gynaecological Cancer Society Charity Forum, Macmillan Cancer Support and the Royal College of Nursing.
Eve representatives currently sign on several committees which are leading innovation within gynaecological cancer diagnosis and prevention this includes:
- ALDO Trial committee, piloting a new screening programme for women at high risk of familiar ovarian cancer development
- International Consensus Paper on Lynch Syndrome, co-ordinated by Manchester University, Emma Crosbie
- Implementation of Mainstreaming Genomics Group, coordinated with NHS England and working alongside HEE, PHE and Macmillan, Dany Bell
- Healthcare Charities group, CNS sub group
- Queens Nursing Institute
- Chair of Healthcare & Workforce Modelling
The Eve Appeal provides a voice research findings, evidence and insights from working with both clinicians and patients to other forums including those convened by Ministers to discuss the NHS Long Term Plan, national cancer screening protocols and health education.
We are a member of the Sex Education Forum and are taking forward work to implement better education around anatomy, menstrual health, screening and gynaecological cancer risk factors such as HPV.
We embrace research proposals from a multi-disciplinary perspective and have funded programmes led by surgeons, specialist nurses, doctors, pathologists and biomathematicians. We support world-class medical research in the early diagnosis, risk prediction and prevention of gynaecological cancers:
- University College London
- Cambridge University
- Bart’s Cancer Institute, Queen Mary University London
- Karolinska Institutet, Sweden
- Charles University Hospital, Czech Republic
- Haukeland University Hospital, University of Bergen, Norway
- European Institute of Oncology, Italy
- University Hospital Southampton NHS Foundation Trust, United Kingdom
- Ludwig-Maximilians Universität, Munich, Germany
- London School of Hygiene and Tropical Medicine, United Kingdom
- Erasmus MC, The Netherlands
- Oncotyrol Center for Personalized Cancer Medicine, Austria
- Max Planck Institute for Human Development, Germany
- GATC Biotech, Germany
- University of Manchester team at St Mary’s
- Imperial College
- Harvard Medical School
- University of Southern California
We welcome co-funding large scale research programmes and have worked alongside funders including EU Horizon 2020, Cancer Research UK, the National Institute for Health Research, the Medical Research Council, and the Departments of Health in England, Wales and Scotland.